問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberMS202611_0001
NCT Number(ClinicalTrials.gov Identfier)-
Completed

2024-06-01 - 2027-06-30

Phase II

Recruiting5

ICD-10C67.9

Malignant neoplasm of bladder, unspecified

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9188.9

Malignant neoplasm of bladder, part unspecified

-

  • Trial Applicant

    IQVIA RDS Taiwan Ltd.

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/05/16

Investigators and Locations

Principal Investigator Mu-Hsin Chang Division of Hematology & Oncology
Taipei Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Po-Jung Su Division of Hematology & Oncology
Linkou Chang Gung Medical Foundation

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 林建良 Division of Hematology & Oncology
Chi Mei Hospital, Liouying

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yu-Li Su Division of Hematology & Oncology
Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Yu-Chieh Tsai
National Taiwan University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

-

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    10 participants

  • Global

    90 participants

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB